The Dementia Discovery Fund, which is being established by the UK government with initial commitments totalling $100 million, brings together leading pharmaceutical companies, the UK government and Alzheimer’s Research UK to address the rising threat posed by dementia by supporting research into future treatments.

The fund aims to identify and nurture promising new avenues of research from around the world in the field of dementia. It is hoped that by providing critical financial support and expert advice during the early stages of research, the development of innovative new treatments for this disease could be accelerated.

The Dementia Discovery Fund will be structured as a typical venture capital fund, but will be the first to focus solely on dementia research. The Fund will comb the global research community for the most promising early stage research to invest in. A scientific advisory board of representatives from each of the partner organisations will provide expert scientific input during the selection of research programmes, as well as providing ongoing advice during pre-clinical and early clinical development. Partners will then be sought for the progression of promising assets through the clinical development pipeline, the intention being that proceeds from licensing or sale of such programmes will be returned to the Fund and its investors. The Fund will appoint a professional investment manager in due course, which will be responsible for its financial governance and investment decisions.

Source: Reuters

Links

Link to Reuters News Story

18 ožujka, 2015